1. Home
  2. HAE vs NAMS Comparison

HAE vs NAMS Comparison

Compare HAE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$80.37

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.52

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAE
NAMS
Founded
1971
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.1B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
HAE
NAMS
Price
$80.37
$35.52
Analyst Decision
Buy
Strong Buy
Analyst Count
9
10
Target Price
$84.38
$45.80
AVG Volume (30 Days)
854.6K
1.1M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
42.54
N/A
EPS
3.44
N/A
Revenue
$1,327,850,000.00
$35,243,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.01
N/A
P/E Ratio
$24.30
N/A
Revenue Growth
N/A
4.91
52 Week Low
$47.32
$14.06
52 Week High
$87.32
$42.00

Technical Indicators

Market Signals
Indicator
HAE
NAMS
Relative Strength Index (RSI) 60.16 44.82
Support Level $82.30 $34.59
Resistance Level $87.32 $36.60
Average True Range (ATR) 2.21 1.83
MACD -0.91 -0.38
Stochastic Oscillator 19.56 13.37

Price Performance

Historical Comparison
HAE
NAMS

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: